RxDoctor Payments Data

John Doolan, DPM

Foot & Ankle Surgery · New York, NYNPI 1073540480

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (37.3%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 57 manufacturers reported payments, led by Organogenesis Inc. at 32.2% of the total. Among foot & ankle surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$86,740in general payments, 2019–2025

Across 445 payments — averaging $194.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$28K
  • Royal Biologics, Inc.$16K
  • Polynovo North America LLC$12K
  • Gramercy Extremity Orthopedics LLC$8K
  • Musculoskeletal Transplant Foundation Inc.$3K
  • Stryker$2K
  • plus $18K from 51 others

What the payments were for

  • Royalty or licence$6791%
  • Consulting fees$22,18726%
  • Speaking & faculty fees$23,66327%
  • Travel & lodging$6,6168%
  • Food & beverage$32,35537%
  • Education$1,2401%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,740 in reported general payments places this provider in the 95th percentile of 652 foot & ankle surgery providers in New York.

See all foot & ankle surgery providers in New York

Medicare billing

Part B allowed, 2024
$376,389
Medicare patients
397
Services billed
3,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.24$8,260
Celecoxib12$618
Ammonium Lactate20$555
Terbinafine Hcl60$452
Ketoconazole37$429
Gabapentin11$190
Diclofenac Sodium18$156
Mupirocin11$57
Meloxicam19$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$1,421$8,26024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 foot & ankle surgery providers in New York.

Other foot & ankle surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →